Drilling Deeper for Treatment Choices in Diabetic Macular Edema
- PMID: 26606738
- PMCID: PMC11574779
- DOI: 10.1001/jamaophthalmol.2015.4652
Drilling Deeper for Treatment Choices in Diabetic Macular Edema
Conflict of interest statement
Comment on
-
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.JAMA Ophthalmol. 2016 Feb;134(2):127-34. doi: 10.1001/jamaophthalmol.2015.4599. JAMA Ophthalmol. 2016. PMID: 26605836 Free PMC article. Clinical Trial.
References
-
- Wells JA, Glassman AR, Jampol LM, et al.; Diabetic Retinopathy Clinical Research Network. Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema [published online November 25, 2015]. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2015.4599. - DOI - PMC - PubMed
-
- Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema: relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Arch Ophthalmol. 1995;113(9):1144–1155. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical